Evidence map›Paper›PMID 37062906›Full record

ReviewBrain and behavior2023

HMGB1, angel or devil, in ischemic stroke.

Bin Gao, Shuwen Wang, Jiangfeng Li, Nannan Han, Hanming Ge, Gejuan Zhang, Mingze Chang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Brain and behavior, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Investigating the Potential of CDDO-Me as an HMGB1 Inhibitor in Mitigating Cerebral Ischemia-Reperfusion Injury.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Emerging Roles of High-mobility Group Box-1 in Liver Disease.Journal of clinical and translational hepatology · 2024
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Bin GaoDepartment of Neurology, Xi'an No. 3 Hospital, the Affiliated Hospital of Northest University, Xi'an, Shaanxi, P.R. China.ORCID 0000-0002-8036-3877
Shuwen WangDepartment of Neurology, Xi'an No. 3 Hospital, the Affiliated Hospital of Northest University, Xi'an, Shaanxi, P.R. China.
Jiangfeng LiDepartment of Neurosurgery, the First Hospital of Yu'lin, Yu'lin, Shaanxi, China.
Nannan HanDepartment of Neurology, Xi'an No. 3 Hospital, the Affiliated Hospital of Northest University, Xi'an, Shaanxi, P.R. China.
Hanming GeDepartment of Neurology, Xi'an No. 3 Hospital, the Affiliated Hospital of Northest University, Xi'an, Shaanxi, P.R. China.
Gejuan ZhangDepartment of Neurology, Xi'an No. 3 Hospital, the Affiliated Hospital of Northest University, Xi'an, Shaanxi, P.R. China.
Mingze ChangDepartment of Neurology, Xi'an No. 3 Hospital, the Affiliated Hospital of Northest University, Xi'an, Shaanxi, P.R. China.
Xi'an Chest Hospital · CNYichang Central People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHigh-mobility group box 1 protein (HMGB1) is extensively involved in causing ischemic stroke, pathological damage of ischemic brain injury, and neural tissue repair after ischemic brain injury. However, the precise role of HMGB1 in ischemic stroke remains to be elucidated.

methodsComprehensive literature search and narrative review to summarize the current field of HMGB1 in cerebral ischemic based on the basic structure, structural modification, and functional roles of HMGB1 described in the literature.

resultsStudies have exhibited the crucial roles of HMGB1 in cell death, immunity and inflammation, thrombosis, and remodeling and repair. HMGB1 released after cerebral infarction is extensively involved in the pathological injury process in the early stage of cerebral infarction, whereas it is involved in the promotion of brain tissue repair and remodeling in the late stage of cerebral infarction. HMGB1 plays a neurotrophic role in acute white matter stroke, whereas it causes sustained activation of inflammation and plays a damaging role in chronic white matter ischemia.

conclusionsHMGB1 plays a complex role in cerebral infarction, which is related to not only the modification of HMGB1 and bound receptors but also different stages and subtypes of cerebral infarction. future studies on HMGB1 should investigate the spatial and temporal dynamics of HMGB1 after cerebral infarction. Moreover, future studies on HMGB1 should attempt to integrate different stages and infarct subtypes of cerebral infarction.

Indexed as

Brain InjuriesBrain IschemiaHMGB1 ProteinIschemic StrokeStrokeCerebral InfarctionHumansInflammationHMGB1 ProteinHMGB1 protein, humanatherosclerosisHMGB1immune tissue repairischemic strokepathological mechanism

Identifiers

PMID37062906
PMCPMC10176004
OpenAlexW4366084221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.